Appendices 272 BIBLIOGRAPHY This thesis Prelude 1. Polak TB, Cucchi DGJ, van Rosmalen J. Behandeling met een niet-geregistreerd geneesmiddel [Expanded Access in The Netherlands: prescribing unregistered medicine]. Ned Tijdschr Geneeskd. 2021 Feb 25;165:D5168. 2. Birkmann A, Marini A, Müller A, Polak TB, Rangaraju M,Sumner M,Trübel H,WaldA,Zimmermann H. Pritelivir for the treatment of resistant HSV infections in immunocompromised patients: update on an ongoing Phase 3 trial and Early Access Program. (Oral at STI & HIV, Chicago 2023) 3. Avery RK, Polak TB, Birkmann A, Truebel H, Gunson S, Sumner M, Dickter J, Neofytos D, and Lee. Immunocompromised Patients with Resistant HSV Infections: Results of the International Early Access Program of Pritelivir. (Poster at SSAI/ICHS, Basel 2022) 4. Choquet S, Uttenthal B, Chaganti S, Comoli P, Trappe RU, Friedetzky A, Xing B, Li X, Polak TB, Gamelin L, Terwey J-H, and Dierickx D. Demographics and Treatment Outcomes in Patients with EBV+ PTLD Treated with Off-the-Shelf EBV-specific CTL (Tabelecleucel) Under an Ongoing Expanded Access Program in Europe: First Analyses. (Poster at EHA and ASCO, resp. Vienna and Chicago, 2022) ♣ Part I – The clinical merit of expanded access 1. Polak TB, Cucchi DGJ, Ossenkoppele GJ, Uyl-De Groot CA, Cloos J, Zweegman S, Janssen JJWM. Two decades of targeted therapies in acute myeloid leukemia. Leukemia. 2021 Mar;35(3):651660. 2. Cucchi DGJ, Polak TB, Ossenkoppele GJ, Rowe JM, Estey EH. The predictive value of a positive phase 2 ASH abstract for peer-reviewed publication and progression to phase 3. Blood. 2022 Mar 24;139(12):1920-1923. 3. Polak TB, Cucchi DGJ, Darrow JJ, Versteegh MM. Incremental benefits of novel pharmaceuticals in the United Kingdom: A cross-sectional analysis of NICE technology appraisals from 2010 – 2020. BMJ Open. 2022 Apr 8;12(4):e058279.
RkJQdWJsaXNoZXIy MTk4NDMw